Fate Therapeutics price target lowered to $8 from $12 at Mizuho

Mizuho lowered the firm’s price target on Fate Therapeutics to $8 from $12 and keeps a Buy rating on the shares. The target drop is based on a higher share count as the interplay between the current valuation and the company’s lengthening cash runway could result in greater dilution than previously expected, the analyst tells investors in a research note.